Fixed-Duration Therapy for CLL: Side Effects & Costs
- * Ianalumab shows promise: The drug Ianalumab may allow patients with Chronic lymphocytic Leukemia (CLL) to stop continuous daily treatment with Ibrutinib.
- * Shazia Nakhoda, MD (Fox Chase Cancer Center): Highlights the excitement around this data, emphasizing the potential to address both the physical and financial toxicity of long-term continuous...
- * Presented at: ASH Annual Meeting and Exposition, December 6-9, 2025, Orlando.
Here’s a summary of the article, focusing on key data:
Key Findings:
* Ianalumab shows promise: The drug Ianalumab may allow patients with Chronic lymphocytic Leukemia (CLL) to stop continuous daily treatment with Ibrutinib.
* Fixed-duration therapy benefits: Using fixed-duration therapies (like Ianalumab possibly enabling) can definitely help overcome the long-term side effects and financial burden associated with continuous BTK inhibitor therapy (like ibrutinib).
Expert Opinion:
* Shazia Nakhoda, MD (Fox Chase Cancer Center): Highlights the excitement around this data, emphasizing the potential to address both the physical and financial toxicity of long-term continuous treatment.
Study Details:
* Presented at: ASH Annual Meeting and Exposition, December 6-9, 2025, Orlando.
* Reference: Al-Sawaf O, et al. abstract 1.
Disclosures:
* Dr. Nakhoda has financial relationships with several pharmaceutical companies (Serb Pharmaceuticals, AstraZeneca, BeOne Medicines, and Genentech) including research funding and honoraria.
Source:
* healio Interviews.
Healio AI Promotion: The article also includes a promotion for Healio AI, a tool that allows users to ask clinical questions and access a knowledge base including PubMed, trials, guidelines, and Healio’s news coverage.